🇺🇸 FDA
Pipeline program

JBT-101

JBT101-DM-001

Phase 2 small_molecule terminated

Quick answer

JBT-101 for Dermatomyositis is a Phase 2 program (small_molecule) at Corbus Pharmaceuticals Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Corbus Pharmaceuticals Holdings
Indication
Dermatomyositis
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials